You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

T-Cell Lymphomas

  • Authors: Steven Horwitz, MD; Kerry Savage, BSc, MD, MSc, FRCPC; Alison Moskowitz, MD; John Reneau, MD, PhD
  • CME / ABIM MOC / CE Released: 10/18/2022
  • Valid for credit through: 10/18/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.75 ABIM MOC points

    Nurses - 0.75 ANCC Contact Hour(s) (0.5 contact hours are in the area of pharmacology)

    Pharmacists - 0.75 Knowledge-based ACPE (0.075 CEUs)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), physician assistants (PAs), and pharmacists involved in the care of patients with hematologic disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), and other related conditions.

The goal of this activity is that learners will be better able to personalize treatment for patients with cutaneous and peripheral T-cell lymphoma in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Novel approaches for treating T-cell lymphoma
  • Have greater competence related to
    • Selecting evidence-based treatment for patients with T-cell lymphoma
    • Managing adverse events associated with current therapies for patients with T-cell lymphoma
  • Demonstrate greater confidence in their ability to
    • Personalize treatment for patients with T-cell lymphoma in an interprofessional team-based environment


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Steven Horwitz, MD

    Associate Attending Physician
    Department of Medicine
    Lymphoma Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Steven Horwitz, MD, has the following relevant financial relationships:
    Consultant or advisor for: Acrotech; C4 Therapeutics; Daiichi Sankyo; Janssen; Kura; KyowaHakko Kirin; Myeloid; ONO; SeaGen; SecuraBio; Shoreline; Takeda; Trillium; Tubulis; Yingli
    Research funding from: ADC Therapeutics; Affimed; C4 Therapeutics; Celgene; Crispr; Daiichi Sankyo; KyowaHakko Kirin; SeaGen; SecuraBio; Takeda; Trillium; Verastem

  • Kerry Savage, BSc, MD, MSc, FRCPC

    Medical Oncologist
    BC Cancer
    Professor of Medicine, University of British Columbia
    Vancouver, British Columbia, Canada

    Disclosures

    Kerry Savage, BSc, MD, MSc, FRCPC, has the following relevant financial relationships:
    Consultant or advisor for: Bristol Myers Squibb Company; KyowaHakko Kirin; Merck; Novartis; SeaGen
    Research funding from: Bristol Myers Squibb Company
    Other: DSMC: Regeneron
    Steering Committee: BeiGene

  • Alison Moskowitz, MD

    Associate Attending Physician
    Clinical Director, Lymphoma
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Disclosures

    Alison Moskowitz, MD, has the following relevant financial relationships:
    Consultant or advisor for: Affimed; Imbrium; Janpix; Merck; Purdue; SeaGen; Takeda
    Speaker or member of speakers bureau for: Gilead
    Research funding from: ADC Therapeutics; BeiGene; Bristol Myers Squibb Company; Incyte; Merck; Miragen; SeaGen; SecuraBio

  • John Reneau, MD, PhD

    Hematology Specialist
    The Ohio State University
    Wexner Medical Center
    Columbus, Ohio

    Disclosures

    John Reneau, MD, PhD, has the following relevant financial relationships:
    Research funding from: ADC Therapeutics; Bristol Myers Squibb Company; Corvus; Incyte; Kymera; Merck; SeaGen, Inc.

Editor

  • John Churchwell, MS, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    John Churchwell, MS, PhD, has the following relevant financial relationships: he was employed by Medtronic (ended 2021)  

Compliance Reviewer

  • Yaisanet Oyola, MD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Yaisanet Oyola, MD, has no relevant financial relationships.

Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 0.75 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape, LLC designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) (Universal Activity Number JA0007105-0000-22-359-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

T-Cell Lymphomas

Authors: Steven Horwitz, MD; Kerry Savage, BSc, MD, MSc, FRCPC; Alison Moskowitz, MD; John Reneau, MD, PhDFaculty and Disclosures

CME / ABIM MOC / CE Released: 10/18/2022

Valid for credit through: 10/18/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Novel Approaches in Cutaneous and Peripheral T-Cell Lymphomas

Do you know the best practices for managing cutaneous and peripheral T-cell lymphomas? Watch to learn more.
John Reneau, MD, PhD

Case Study: Peripheral T-Cell Lymphoma

Hear engaging cases that address best practices for individualized treatment strategies in peripheral T-cell lymphoma.
Kerry Savage, BSc, MD, MSc, FRCPC

Case Study: Cutaneous T-Cell Lymphoma

Learn more about approaches to individualized treatment for cutaneous T-cell lymphoma in this instructive presentation.
Alison Moskowitz, MD

Learning Feedback Questions

The goal of this activity is that learners will be better able to personalize treatment for patients with cutaneous and peripheral T-cell lymphoma in an interprofessional team-based environment by integrating clinical trial data and evidence-based recommendations on novel therapies.

Please answer these questions to complement your learning experience.